Glimepirid Stada

Glimepirid Stada is a prescription oral medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea used to manage blood glucose in adults with type 2 diabetes mellitus. Marketed in the European Union, the product is supplied as tablets for oral administration; specific strengths may vary according to local labeling. It is intended for chronic therapy and should be taken according to a healthcare professional’s prescription.

Glimepirid Stada is indicated for the long‑term control of hyperglycemia in patients with type 2 diabetes mellitus when diet, exercise, and lifestyle measures alone are insufficient. It may be used as monotherapy or in combination with other antidiabetic agents.

- As initial oral therapy for newly diagnosed type 2 diabetes. - As add‑on to metformin when glycemic targets are not met. - In combination with a DPP‑4 inhibitor or SGLT2 inhibitor for enhanced glucose lowering. - For patients who can tolerate sulfonylureas and have adequate renal function.

Glimepirid Stada can cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common: - Mild hypoglycemia (especially with missed meals). - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain. - Skin rash or pruritus.

Serious: - Severe hypoglycemia requiring assistance. - Allergic reactions such as angioedema or Stevens‑Johnson syndrome. - Hepatic dysfunction. - Hematologic abnormalities (e.g., leukopenia, thrombocytopenia).

Before prescribing Glimepirid Stada, clinicians should evaluate several safety considerations.

- Assess renal and hepatic function; dose adjustment may be needed. - Review history of hypersensitivity to sulfonylureas. - Caution in elderly patients due to increased hypoglycemia risk. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Monitor blood glucose regularly to detect hypoglycemia. - Educate patients on recognizing and managing low blood sugar episodes.

Glimepirid Stada may interact with other medicines, altering its efficacy or safety profile.

Avoid: - Concurrent use with other sulfonylureas or meglitinides (increased hypoglycemia). - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride levels. - MAO‑B inhibitors (e.g., selegiline) which can potentiate hypoglycemic effect.

Use with caution: - Beta‑blockers (may mask hypoglycemia symptoms). - Thiazide diuretics (can affect glucose tolerance). - ACE inhibitors or ARBs (monitor renal function). - Alcohol (enhances hypoglycemia risk).